New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
LaunchTrends(TM): Uloric(R) is a three wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists and Primary Care Physicians will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of Uloric(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
SOURCE BioTrends Research Group, Inc.